Axsome Therapeutics (AXSM) Retained Earnings (2015 - 2026)

Axsome Therapeutics has reported Retained Earnings for 12 years, with the latest figure at -$1.4 billion in Q1 2026.

• Quarterly Retained Earnings fell 15.93% year-over-year to -$1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.4 billion (down 15.93% YoY) and the FY2025 annual result came in at -$1.3 billion, down 16.31% from the prior year.
• Retained Earnings eased to -$1.4 billion in Q1 2026 per AXSM's latest filing, from -$1.3 billion in the prior quarter.
• Over five years, Retained Earnings peaked at -$448.8 million in Q1 2022 and troughed at -$1.4 billion in Q1 2026.
• A 5-year average of -$902.9 million and a median of -$903.9 million in 2024 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2024 and 2026: Retained Earnings sank 48.78% in 2024, then declined 15.93% in 2026.
• Over 5 years, Retained Earnings stood at -$596.3 million in 2022, then tumbled by 40.12% to -$835.6 million in 2023, then plunged by 34.37% to -$1.1 billion in 2024, then dropped by 16.31% to -$1.3 billion in 2025, then slipped by 4.94% to -$1.4 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$1.4 billion, -$1.3 billion, and -$1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.